Clinical Trials
9
Active:0
Completed:8
Trial Phases
1 Phases
Phase 4:1
Drug Approvals
20
HSA:20
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 4
1 (100.0%)Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06734585
- Locations
- 🇭🇰
HK852001, Hong Kong, Hong Kong
A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia
Completed
- Conditions
- Metastatic Urothelial Cancer
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 287
- Registration Number
- NCT06505746
- Locations
- 🇰🇷
KR00001, Seoul, Korea, Republic of
A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
Completed
- Conditions
- Menopause
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 3399
- Registration Number
- NCT04553029
- Locations
- 🇨🇳
Site CN86002, Beijing, China
🇰🇷Site KR82001, Seoul, Korea, Republic of
🇨🇳Site TW88601, Taipei, Taiwan
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Completed
- Conditions
- Overactive Bladder (OAB)
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 6295279
- Registration Number
- NCT03903094
- Locations
- 🇦🇺
Site AU61001, Melbourne, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Completed
- Conditions
- Overactive Bladder (OAB)
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found